DUBAI, United Arab Emirates and WUHU, China, Nov. 20, 2026 (GLOBE NEWSWIRE) — LEPAS, Chery Auto’s Premium NEV brand, officially entered the Gulf market with a regional brand launch in Dubai. Its first model in the region, the LEPAS L8, is now on sale in the UAE, starting at AED 99,999, with launches in Kuwait, Qatar and other markets to follow.

image1

As the Gulf accelerates its transition to new energy mobility, policy support and interest in electrified vehicles continue to grow. Customers seek vehicles that combine distinctive design with the ability to handle diverse road and climate conditions. The LEPAS L8 PHEV meets these expectations as an Elegant All-round Premium SUV, bringing together refined design, confident driving and intelligent technology.

The first 100 customers will receive exclusive benefits, including insurance, maintenance and complimentary roadside assistance. LEPAS also offers a 7-year/200,000-km vehicle warranty and an 8-year/160,000-km warranty for the electric powertrain system, providing added peace of mind.

Elegant Design: Where Natural Energy Meets Spacious Comfort

Created for customers who appreciate bold design and refined details, the LEPAS L8 PHEV embodies Leopard Aesthetics, inspired by the agility and strength of the leopard. Flowing body lines and the distinctive Leaping Leopard Beltline create a dynamic sense of movement, while the Pioneering Leopard Avant-Garde Front Fascia and Leopard-Eye LED Headlights give the SUV a commanding yet expressive presence.

image2

With a 2,800-mm wheelbase and 66.5% space utilization, the LEPAS L8 PHEV offers a spacious five-seat layout. Its wraparound cabin creates a welcoming atmosphere, complemented by Cloud Comfort Lounge Seats and excellent NVH performance for a quiet, comfortable ride. A 507L cargo capacity, 47 Ingenious Storage Spaces and versatile seating configurations make room for passengers and everyday essentials alike, turning the cabin into a comfortable living space on the move.

Elegant Driving: Smart Assistance Makes Journeys Easier

Built on the intelligent LEX Platform, the LEPAS L8 PHEV features APA and RPA Parking Assistance to simplify parking in busy urban environments, from maneuvering in tight spaces to parking in designated spaces in multi-level garages. Its 16 ADAS features also assist with following distance, lane keeping and hazard detection, making daily commutes and intercity journeys easier.

image3

For greater awareness in busy streets and at turns with limited visibility, the LEPAS L8 PHEV features 540° Panoramic View. A cage-style body structure, six airbags and a battery pack with IP68 and IPX9K protection ratings provide additional layers of safety and reassurance.

Local Adaptation: Balancing Driving Efficiency with Everyday Needs

Powered by LEPAS Super Hybrid, the L8 PHEV balances energy efficiency with extended range for daily commutes and longer journeys. Under the NEDC test cycle, it delivers a combined range of up to 1,300 km and an all-electric range of more than 100 km, with charging from 30% to 80% taking just 20 minutes. Whether commuting or travelling beyond the city, customers can enjoy greater flexibility on the road.

image4

The L8 PHEV is also adapted to the region’s hot climate. Its upgraded air-conditioning system, combined with UV-Blocking and Heat-Insulating Glass, helps keep the cabin cool under intense sunlight. Meanwhile, the AQS Air Quality Monitoring System monitors cabin air quality, ensuring a fresh and comfortable interior.

image5

The L8 PHEV marks the beginning of LEPAS’s broader presence in the Middle East. More LEPAS NEV models will follow, expanding choices for local customers. The brand will also continue to co-create with customers across the region, drawing on diverse cultures and perspectives to shape new expressions of elegant living and bring its brand promise, “Drive Your Elegance,” to more people worldwide.

About LEPAS

LEPAS is Chery Auto’s Premium NEV brand, dedicated to creating elegant mobility experiences for users worldwide. Committed to becoming the Preferred Brand for Elegant Mobility Life, LEPAS brings together Leopard Aesthetics, Elegant Technology, and Exquisite Space – transforming elegance into a driving experience you can see, feel, and trust. Supported by a growing global dealer network of more than 500 sales and service outlets, LEPAS is expanding its international footprint through localized operations, delivering products and experiences tailored to users across global markets.

About Chery Auto

Founded in 1997, Chery Auto is a global automotive manufacturer specializing in vehicle development, intelligent technologies, and new energy solutions. The company operates in more than 130 countries and regions, supported by a strong international network of research, production, and strategic partnerships. Chery Auto has remained China’s No. 1 passenger vehicle exporter among Chinese brands for 23 consecutive years. Guided by its global philosophy of “In somewhere, For somewhere, Be somewhere,” Chery Auto is committed to advancing sustainable mobility through continuous innovation and global collaboration.

Media Contact
Company Name: LEPAS International
Contact Person: Vincy wang
E-mail: GlobalPR@lepasinternational.com
Company Official Website: https://lepasinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/e2466533-5b55-4d0f-b172-065df7e03bba

https://www.globenewswire.com/NewsRoom/AttachmentNg/a5a79c2a-1fd4-4de2-a48b-78929f0bddd3

https://www.globenewswire.com/NewsRoom/AttachmentNg/871f3fd9-6701-4509-be88-6fa51b0e8f0e

https://www.globenewswire.com/NewsRoom/AttachmentNg/fb867582-cebc-444f-83fb-0c4c894976f1

https://www.globenewswire.com/NewsRoom/AttachmentNg/9ac67a3f-7cd4-4d9a-83ee-4fce238ee461

  • Company receives Complete Response Letter from FDA for Deramiocel BLA
  • Conference call and webcast Monday, November 23, at 8:30 a.m. ET

SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its resubmitted Biologics License Application (BLA) for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy (DMD). The CRL states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies.

“We are deeply disappointed for the boys and young men living with Duchenne and their families,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer. “Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval. We are reviewing the letter carefully and will share next steps once we have completed our evaluation.”

As of September 30, 2026, the Company had cash, cash equivalents, restricted cash and marketable securities of approximately $198.5 million, which it believes is sufficient to fund its planned operations for at least the next 12 months. The Company is reviewing its operating costs to further extend its cash runway.

Conference Call and Webcast

To participate in the conference call, please dial 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) and reference the conference ID: 27699. Participants may dial in using the numbers above and ask to be joined to the call or click the Call Me™ link for instant telephone access to the event. To participate via a webcast, please click here. A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States, primarily males. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; the contents of, and our response to, the Complete Response Letter and the timing of any resubmission; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, cash runway and planned cost reductions, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission on November 10, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Whether you’re after a budget-friendly pick or the ultimate upgrade, find incredible deals on laptops and desktops for yourself and your loved ones

Fremont, CA, Nov. 20, 2026 (GLOBE NEWSWIRE) — ASUS is kicking off the holiday season with major savings online at the ASUS Store as well as in store and online at Best Buy. From now until December 2, 2026, shoppers will find discounts on a vast selection of laptops and desktops to fit every kind of user.

This Holiday Season, Save Up to 44% on a Wide Range of ASUS Tech!

ASUS Holiday Deals

Explore some of our top holiday picks below:

 

Best Under $1,000:

·        ASUS Vivobook 14 (X1407QA)

o   Pricing and availability: $499.99 at the ASUS Store – you save $400!

o   Best for: Value-conscious consumers who are seeking a practical everyday device.

o   What sets it apart: Powered by the highly efficient Snapdragon® X processor, the ASUS Vivobook 14 delivers fast, responsive performance that’s backed by an impressive up to 29 hours of battery life. With 16GB of LPDDR5X memory and 512GB of storage, it offers the headroom for everyday multitasking, productivity, and entertainment without stretching your budget.

·        ASUS Zenbook 14 (UX3480QA)

o   Pricing and availability: $649.99 at Best Buy – you save $350!

o   Best for: Everyday users who want reliable performance without compromising premium features.

o   What sets it apart: Blending power-efficient Snapdragon® X performance with a vibrant OLED display, an ergonomic keyboard, and a full set of I/O ports in a thin and light all-metal chassis, the ASUS Zenbook 14 delivers an elevated, flagship-style experience for everyday productivity. Its nature-inspired Arctic Blue and Komodo Coral colorways, finished with the ASUS-exclusive Ceraluminum™ lid, add a personal touch of style.

 

Best Portable Powerhouse

·        ASUS Zenbook S14 (UX5406SA)

o   Pricing and availability: $1,199.99 at the ASUS Store – you save $400!

o   Best for: Professionals who don’t want to compromise on performance, portability, or premium design.

o   What sets it apart: Pairing AI-enhanced performance (Intel® Core™ Ultra 7 258V processor, 32GB of memory, and a 1TB SSD) with an ultraportable 0.47-inch, 2.65-pound design, the ASUS Zenbook S14 handles everything from daily computing to demanding workloads on the go. Its vibrant OLED display and immersive audio make it just as enjoyable for entertainment as it is for productivity. The ASUS-exclusive Ceraluminum™ lid in Scandinavian White adds a premium finish that exudes sophistication.

·        ProArt P14 (H7407BA)

o   Pricing and availability: $2,599.99 at Best Buy

o   Best for: Creators who need workstation-class power in a compact, easy-to-carry form factor.

o   What sets it apart: Combining NVIDIA’s RTX Spark Superchip with a 3K ASUS Lumina Pro Tandem OLED display, the ProArt P14 delivers workstation-class performance for creative work, gaming, and on-device AI without the traditional trade-off between power and mobility. Its precision CNC-crafted chassis houses a 90Wh battery for all-day productivity, while thoughtful features such as comprehensive I/O for dongle-free connectivity and a haptic touchpad deliver a refined user experience.

 

Best for Gaming

·        ROG Xbox Ally / ROG Xbox Ally X (RC73)

o   Pricing and availability: Starting at $599.99 for the ROG Xbox Ally and $999.99 for the ROG Xbox Ally X at ASUS Store or Best Buy

o   Best for: Gamers who want the flexibility to enjoy their favorite PC games at home or on the go.

o   What sets it apart: Combining Xbox-inspired controls with the versatility of Windows PC gaming, the ROG Xbox Ally and Ally X deliver a comfortable, console-like handheld experience. Both feature AMD Ryzen™ Z2-series processors and 7-inch 120Hz displays, while the premium Ally X offers enhanced performance, additional memory, and a larger battery for more demanding gaming sessions.

·        ASUS TUF Gaming A14 (FA401EA)

o   Pricing and availability: $1,899.99 at the ASUS Store – you save $300!

o   Best for: Gamers and creators seeking capable gaming performance and everyday versatility in a compact, lightweight laptop.

o   What sets it apart: Powered by the AMD Ryzen™ AI Max+ 392 processor with Radeon™ 8060S integrated graphics, the ASUS TUF Gaming A14 balances gaming and creative performance without a dedicated GPU. Its 14-inch 2.5K 165Hz display delivers smooth, detailed visuals, while its lightweight 3.26-pound design makes it easy to transition between gaming, productivity, and entertainment on the go.

·        ROG Zephyrus G16 (GU606AR)

o   Pricing and availability: $2,779.99 at Best Buy – you save $620!

o   Best for: Enthusiast gamers and content creators seeking premium gaming performance, stunning visuals, and portability.

o   What sets it apart: Pairing an Intel® Core™ Ultra 9 386H processor with NVIDIA® GeForce RTX™ 5070 Ti Laptop graphics, the ROG Zephyrus G16 delivers powerful performance for demanding games and creative workloads. Its 16-inch 2.5K ROG Nebula HDR OLED display with a 240Hz refresh rate provides stunning visuals, while its sleek, approximately 4.3-pound aluminum chassis makes high-performance gaming more portable

·        ROG GM700 (GM700TZ)

o   Pricing and availability: $2,999.99 at the ASUS Store

o   Best for: Serious PC gamers seeking powerful, ready-to-play desktop performance without the hassle of building their own system.

o   What sets it apart: Designed for high-performance gaming straight out of the box, the ROG GM700 combines AMD Ryzen™ processing with powerful dedicated graphics to handle demanding AAA titles and multitasking. Its spacious 58-liter chassis prioritizes airflow and cooling while providing room for future upgrades, making it a compelling prebuilt desktop for gamers who want both performance and flexibility.

 

AVAILABILITY AND PRICING

Please note: All prices, discounts, and promotional timelines are subject to change at any time without notice. Promotional products are subject to availability. 

Check out more deals at the ASUS Store.

For more information, please visit https://www.asus.com/us/ or contact your local ASUS representative.

 

Press Contacts

ASUS USA PR Team: asuspr_usa@asus.com

 

Notes to Editors

Top Deals at the ASUS Store: https://us.asus.click/pr_bfcm2026

ASUS USA Pressroom: https://www.asus.com/us/news/

ASUS USA Facebook: https://www.facebook.com/asus.n.america/

ASUS USA Twitter: https://twitter.com/ASUSUSA

 

 

About ASUS

ASUS (2357.TW) is an innovative technology leader delivering the world’s most comprehensive AI solutions across Infrastructure, Physical AI, AI PC/Devices, and Engineering the AI Advantage. Guided by its “Ubiquitous AI. Incredible Possibilities” strategy, ASUS is bringing enterprise-to-edge AI to life. The ASUS portfolio also includes the ROG and ProArt sub-brands, which serve gamers and creators worldwide.

 

 

 

 

 

Press Inquiries

Anthony Spence
asuspr_usa [at] asus.com
https://www.asus.com/
48720 Kato Road | Fremont, CA 94538

TOKYO, Nov. 20, 2026 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that it received written notice dated November 20, 2026, from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1), because the Company filed its Form 20-F for the year ended December 31, 2025 on November 18, 2026. Accordingly, Nasdaq has closed the matter relating to the delayed filing of the Company’s annual report.

The Company remains subject to the previously disclosed minimum bid price deficiency under Nasdaq Listing Rule 5550(a)(2) and has until April 5, 2027 to regain compliance with that requirement. Nasdaq’s confirmation regarding the periodic filing requirement does not resolve this separate deficiency.

About MEDIROM Group
MEDIROM Group operates approximately 281 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.

About MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Website: https://medirom.co.jp/en
Contact: ir@medirom.co.jp

Not for distribution to United States Newswire Services or for dissemination in the United States

VANCOUVER, British Columbia, Nov. 20, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX- V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce that it has closed a non-brokered private placement offering (the “Offering”) of national flow-through shares in the capital of Brixton (the “FT Shares”) at a price of $0.68 per FT Share. In connection with closing the Offering, the Company issued 1,470,000 FT Shares for gross proceeds of $999,600.00.

The gross proceeds from the sale of FT Shares will be used to incur “Canadian exploration expenses” and “flow-through mining expenditures” as defined in the Income Tax Act (Canada). Exploration expenditures are mainly for exploration and drilling at the Company’s Langis Silver-Cobalt Project in Ontario.

All securities issued in connection with the Offering are subject to a hold period of four months and one day expiring on March 21, 2027 pursuant to applicable Canadian securities laws.

No finder’s fees were paid in connection with closing the Offering.

Option Grant

The Company’s Board has granted incentive stock options (each, an “Option”) to directors, officers, employees and consultants entitling the purchase of an aggregate of 1,840,000 common shares in the capital of the Company at a price of $0.465 for a period of 10 years. The Options will vest immediately with the exception of Options granted to investor relations personnel, which will vest in stages over 12 months from the date of grant with one-quarter of the Options granted to investor relations personnel vesting every three-month period following the date of grant in accordance with the policies of the TSX Venture Exchange.

About Brixton Metals Corporation

Brixton Metals is a Canadian exploration company focused on advancing its mining projects. Brixton wholly owns five exploration projects: the Langis and Hudson Bay silver Projects in Ontario; the Thorn copper-gold-silver-molybdenum Project in NW British Columbia; the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc.; and the Atlin Goldfields Project in northwest BC. Brixton holds an option to acquire a 100% interest in the silver-focused Silvergruvan Project in Sweden. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries, please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707.

Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward-looking information under applicable securities laws. Forward-looking information are statements and information that relate to future, not past, events. In this context, forward-looking information often addresses expected future business and financial performance, and often contains words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”; information and statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All information other than information of historical fact included herein are forward-looking information, including, without limitation, information regarding the Company’s business plans and strategies of operations; and use of proceeds of the Offering. By its nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking information is based on management’s beliefs, estimates and opinions on the date that such information is provided and the Company undertakes no obligation to update forward-looking information if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking information. Brixton does not undertake to update any forward-looking information except in accordance with applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.

BRENTWOOD, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (“Surgery Partners”) (Nasdaq: SGRY) announced today the results of the previously announced solicitation of consents (the “Consent Solicitation”) by its indirect wholly owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), from holders (“Holders”) of its outstanding $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032 (CUSIP Nos. 86881W AF9 / U86786 AD9 / U86786 AE7; ISINs US86881WAF95 / USU86786AD98 / USU86786AE71) (the “Notes”) to certain proposed amendments (the “Proposed Amendments”) to the indenture governing the Notes, dated as of April 10, 2024 (as supplemented, the “Indenture”), among the Issuer, the guarantors party thereto and Wilmington Trust, National Association, as trustee (the “Trustee”). The Consent Solicitation was made upon the terms and subject to the conditions set forth in the Issuer’s Consent Solicitation Statement, dated November 16, 2026 (as amended by Amendment No. 1 thereto, dated November 16, 2026, and Amendment No. 2 thereto, dated November 18, 2026, the “Consent Solicitation Statement”).

The Consent Solicitation expired at 5:00 p.m., New York City time, on November 20, 2026 (the “Expiration Time”). As of the Expiration Time, according to information provided by S&P Global Inc., the information and tabulation agent for the Consent Solicitation, the Issuer had received the requisite consents with respect to the Notes (the “Requisite Consents”) to effect the Proposed Amendments.

As previously announced, on October 23, 2026, Surgery Partners entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 thereto, dated as of November 8, 2026, and as it may be further amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with Spyglass Topco, LLC (“Topco”), Spyglass Merger Subsidiary, Inc., a wholly owned subsidiary of Topco (“Merger Sub”), and, solely for the limited purposes set forth therein, Bon Secours Mercy Health, Inc. (“BSMH”). Pursuant to the Merger Agreement, Merger Sub will merge with and into Surgery Partners, with Surgery Partners surviving as a wholly owned subsidiary of Topco (the “Merger”).

The Proposed Amendments will amend the Indenture to (i) provide that, concurrently with and following the consummation of the Merger in accordance with the terms of the Merger Agreement on or prior to the date that is five business days after the End Date (as defined in the Merger Agreement), each of BSMH, HealthSpan Partners, a 501(c)(3) Ohio corporation affiliated with BSMH, and their respective affiliates, and certain groups of which any of them are members, will be “Permitted Holders” under the Indenture, in addition to the existing Permitted Holders, and (ii) add to, amend, supplement or change certain other defined terms in the Indenture related to the foregoing. Except for the Proposed Amendments, all existing terms of the Notes and the Indenture will remain unchanged, and the Proposed Amendments will not alter the Issuer’s obligation to pay the principal of or interest on the Notes or the stated interest rate or maturity date of the Notes.

The Issuer intends to execute a supplemental indenture to the Indenture setting forth the Proposed Amendments (the “Supplemental Indenture”) on or around November 24, 2026. The Supplemental Indenture will become effective upon its execution and delivery, but the Proposed Amendments will become operative only immediately prior to the consummation of the Merger, provided that the Consent Fee has been paid. Once operative, the Proposed Amendments will be binding on all Holders, including those that did not deliver consents. If the Consent Fee is paid but the Merger is not consummated on or prior to the date that is five business days after the End Date, the Proposed Amendments will not become operative, and Holders that received the Consent Fee will retain it.

Holders who validly delivered (and did not validly revoke) consents prior to the Expiration Time will receive a cash payment equal to $5.00 per $1,000 in principal amount of Notes for which such consents were delivered (the “Consent Fee”). The Issuer expects to pay the Consent Fee on November 24, 2026, whether or not the Merger is consummated.

Jefferies LLC acted as solicitation agent and S&P Global Inc. acted as information and tabulation agent in connection with the Consent Solicitation. Questions regarding the Consent Solicitation may be directed to Jefferies LLC at (212) 284-2368 (collect) or to S&P Global Inc. at (212) 849-3880 (banks and brokers) or (888) 593-9546 (toll-free), or by email at consentoffer@spglobal.com.

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell the Notes or any other securities and does not constitute a solicitation of consents with respect to the Notes or any other securities. The Consent Solicitation was made only by, and pursuant to the terms of, the Consent Solicitation Statement, and the information in this press release is qualified in its entirety by reference to the Consent Solicitation Statement.

About Surgery Partners

Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.

Additional Information and Where to Find It

In connection with the proposed acquisition by an affiliate of BSMH of the Company (the “Transactions”), the Company will file with the Securities and Exchange Commission (the “SEC”) a proxy statement (the “Proxy Statement”), a definitive version of which will be mailed or otherwise provided to its stockholders. The Company and certain other filing persons intend to jointly file a transaction statement on Schedule 13E-3 (the “Schedule 13E-3”). The Company may also file other documents with the SEC regarding the proposed Transactions. BEFORE MAKING ANY VOTING DECISION, THE COMPANY’S STOCKHOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT AND THE SCHEDULE 13E-3 IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AND ANY OTHER DOCUMENTS FILED WITH THE SEC AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO IN CONNECTION WITH THE PROPOSED TRANSACTIONS OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES TO THE PROPOSED TRANSACTIONS. Investors and security holders may obtain free copies of the Proxy Statement, the Schedule 13E-3 and other documents that the Company files with the SEC (when available) from the SEC’s website at www.sec.gov and the Company’s website at ir.surgerypartners.com. In addition, the Proxy Statement, the Schedule 13E-3 and other documents filed by the Company with the SEC (when available) may be obtained from the Company free of charge by directing a request to the Company’s Investor Relations at IR@surgerypartners.com.

Participants in the Solicitation

The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the proposed Transactions. Information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of the stockholders of the Company in connection with the proposed Transactions, including a description of their respective direct or indirect interests, by security holdings or otherwise will be set forth in the Proxy Statement and Schedule 13E-3 and other materials to be filed with the SEC. You may also find additional information about the Company’s directors and executive officers in the Company’s proxy statement for its 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 23, 2026 (the “Annual Meeting Proxy Statement”) , including under the sections entitled “Security Ownership of Certain Beneficial Owners and Management”, “Proposal No. 1 Election of Directors”, and “Executive Officers” therein. To the extent holdings of securities by potential participants (or the identity of such participants) have changed since the information printed in the Annual Meeting Proxy Statement, such information has been or will be reflected in the Company’s Statements of Change in Ownership on Forms 4 filed with the SEC. The Company’s stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed Transactions, including the interests of the Company’s directors and executive officers in the proposed Transactions, which may be different than those of the Company’s stockholders generally, by reading the Proxy Statement and Schedule 13E-3 and other relevant materials to be filed with the SEC relating to the proposed Transactions. You can obtain free copies of these documents from the Company using the contact information above.

No Offer

No person has commenced soliciting proxies in connection with the proposed Transactions referenced in this communication, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities, nor a solicitation of any vote or approval.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements. Forward-looking statements generally relate to future events, the Company’s future financial or operating performance or the proposed Transactions. All statements other than statements of historical facts contained in this communication, including statements regarding the proposed Transactions, the Consent Fee, the Proposed Amendments and their expected timing, completion and effects, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “likely,” “may,” “might,” “should,” “plans,” “potential,” “projects,” “will,” or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions.

Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors. Important factors that could cause actual outcomes or results to differ materially from the forward-looking statements include, but are not limited to, (a) the ability of the parties to consummate the proposed Transactions in a timely manner or at all; (b) the satisfaction (or waiver) of closing conditions to the consummation of the proposed Transactions; (c) the potential impact of the unsolicited proposal from a third party or possibility that more competing offers may be made; (d) potential delays in consummating the proposed Transactions; (e) the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed Transactions that could delay the consummation of the proposed Transactions or cause the parties to abandon the proposed Transactions; (f) the possibility that the Company may not receive the requisite stockholder approval for the proposed Transactions; (g) the ability of the Company to timely and successfully achieve the anticipated benefits of the proposed Transactions; (h) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement with BSMH; (i) the Company’s ability to implement its business strategy; (j) significant transaction costs associated with the proposed Transactions, as well as liabilities that are not known, probable or estimable at this time or other unexpected costs, charges or expenses; (k) the possibility that the proposed Transactions may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (l) potential litigation relating to the proposed Transactions; (m) the risk that disruptions from the proposed Transactions will harm the Company’s business, including current plans and operations; (n) risks related to the diversion of management’s time and attention from the Company’s ongoing business operations to matters relating to the proposed Transactions; (o) the ability of the Company to retain and hire key personnel; (p) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Transactions; (q) legislative, regulatory and economic developments affecting the Company’s business; (r) general economic and market developments and conditions; (s) the legal, regulatory and tax regimes under which the Company operates; (t) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed Transactions that could affect the Company’s financial performance; (u) the risk that any announcements relating to the proposed Transactions or the unsolicited proposal from a third party could have adverse effects on the market price of the Company’s common stock, and the risk that such price may decline significantly if the proposed Transactions are not consummated on the anticipated timeline, or at all; (v) restrictions during the pendency of the proposed Transactions that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; and (w) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company’s response to any of the aforementioned factors. There can be no assurance that the proposed Transactions will in fact be consummated. The foregoing list of factors is not exhaustive, and new risks may emerge from time to time. It is not possible for the Company to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

For information regarding other factors that could cause the Company’s results to vary from expectations, please see the “Risk Factors” section of the Company’s periodic report filings with the SEC, including but not limited to the Company’s Form 10-Q filed with the SEC on November 9, 2026 and the Company’s Form 10-K filed with the SEC on March 2, 2026, as well as other documents that may be filed by the Company from time to time with the SEC. These filings, as well as subsequent filings, are available on the investor relations section of the Company’s website at ir.surgerypartners.com or on the SEC’s website at www.sec.gov. The statements in this communication represent the Company’s current beliefs, estimates and assumptions as of the date of this communication. Subsequent events and developments may cause the Company’s views to change. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this communication.

Contacts

Surgery Partners Investor Relations
+1 (615) 234-8940
IR@surgerypartners.com

Dan Scorpio / Jim Polson
FTI Consulting
+1 (872) 344-5356 / +1 (312) 375-5908
Dan.Scorpio@fticonsulting.com / Jim.Polson@fticonsulting.com

PHILADELPHIA, Nov. 20, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 175,840 shares of Iovance’s common stock to twenty-two new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $7.31, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

Received highly favorable notification from the FDA on 56 PMTA SKUs for inclusion on a list of products against which FDA does not intend to prioritize enforcement

PACHA age-gated products will be America’s first age-gated disposables

COSTA MESA, CA, Nov. 20, 2026 (GLOBE NEWSWIRE) — Charlie’s Holdings, Inc. (OTCQB: CHUC) (“Charlie’s” or the “Company”), an industry leader in the premium vapor products space, reported results for the three and nine months ended September 30, 2026, and provided an update on recent business highlights.

Key Financial Highlights for First Nine Months 2026 (compared to first nine months 2025)

  • Revenue increased 19% to $11.3 million
  • Gross profit decreased 3% to $2.4 million
  • Operating loss increased 75% to $3.9 million

Key Balance Sheet Highlights as of September 30, 2026 (compared to December 2025)

  • Cash balance of $0.4 million, compared to $1.3 million
  • Total assets of $11.2 million, compared to $11.6 million
  • Total stockholders’ equity of $1.4 million, compared to $3.4 million

Management Commentary

“Because billions of dollars of illicit vapor products – made by Chinese manufacturers who thumb their noses at the FDA – have flooded the United States this year, Charlie’s sales and profits have taken a hit,” reported Henry Sicignano, President and CEO. “Fortunately, we have the inventory, and the opportunity, to reestablish growing, profitable sales in several states where regulatory enforcement has again become a priority. In this environment, we have redoubled our commitment to regulatory compliance as well as our initiatives to monetize the Company’s 678-SKU PMTA portfolio.”

Mr. Sicignano continued, “Big Tobacco ‘pod systems’ are outdated, provide very low puff counts, and offer few flavor choices. Charlie’s products are modern disposable products… offering much higher puff counts… and hundreds of flavors that adult consumers strongly prefer. For all these reasons, we believe Charlie’s PACHA product line is the best, most robust portfolio of PMTA products in the industry and will likely represent significant value to one or more Big Tobacco strategic partners in 2027.”

As previously reported, Charlie’s has made the well-considered decision to focus intensely on the two strategic priorities that matter most to Company shareholders:

1) Management has shifted its priorities from sales of the PACHAMAMA and SBX product lines to a laser focus on the beta test pilot of PACHA age-gated disposables. The Company has already received tens of thousands of finished age-gated PACHA products in its warehouse. Management has secured test-market purchase commitments from retailers. As soon as the Company’s software licensor completes final tests of its “second generation” consumer app, Charlie’s will begin shipping the age-gated PACHA product to stores. The Company expects that Charlie’s PACHA age-gated products will be America’s first age-gated disposables.

2) The Company has redeployed the priorities of one of Charlie’s largest shareholders. Ryan Stump, Charlie’s co-founder and former COO, has begun work to identify and pursue strategic transactions and/or partnerships with leading global tobacco companies to significantly enhance long-term value for Charlie’s shareholders.

Regulatory Developments

FDA Enforcement Priorities Guidance

In August 2026, the FDA notified Charlie’s that certain of its PACHA products (56 SKUs) for which PMTAs have been submitted have been tentatively identified for inclusion on the FDA’s public-facing webpage of products for which the FDA generally does not intend to prioritize enforcement of premarket authorization requirements — a development the Company views as highly favorable. Inclusion on the FDA’s new list of “low-enforcement priority products” does not, however, constitute FDA marketing authorization, preclude case-by-case enforcement, or bear on whether any PMTA will ultimately be granted. Accordingly, Charlie’s intends to continue pursuing FDA review of its pending PMTAs and to comply with all applicable requirements.

FDA has validated age-gating as a pathway for the legal sale of flavored Electronic Nicotine Delivery System (“ENDS”) products

In May 2026, the FDA granted marketing orders for four Glas Inc. pod products, including “Gold” (mango) and “Sapphire” (blueberry) flavored, age-gated pods. This landmark development validates “age-gating” as a legitimate pathway for the legal sale of flavored ENDS products in the United States. However, Juul Labs filed a patent infringement lawsuit against Glas, Inc. and, under these circumstances, Glas’ newly authorized “fruit flavored” products are unlikely to go on the market in the near term; it is likely that Charlie’s PACHA age-gated products will be America’s first age-gated disposables.

Business Catalysts

Charlie’s plans to begin beta testing PACHA age-gated flavored disposables.

In December 2025, the Company signed a definitive licensing agreement to commercialize the first-ever AI-powered blockchain-based age-gating system for vapor products in the United States. Scheduled to beta test this year, the PACHA test-market initiative will incorporate the age-gating system in a special line of the Company’s flavored ENDS disposables; simultaneously, Charlie’s intends to amend certain of its existing PMTAs with the FDA for PACHA brand ENDS with the youth access prevention system.

Mr. Sicignano commented, “Charlie’s plans to launch PACHA products that have not yet received final FDA authorization follows the example set by one of America’s largest tobacco companies… In recent months, RJ Reynolds’ Vuse business began selling four new fruit flavor pods (berry, fresh mint, peach, and watermelon), all of which were issued FDA Marketing Denial Orders (MDOs). Given that Reynolds has demonstrated it is willing to pursue flavored ENDS commercialization strategies, before final FDA authorization, we believe the strategic calculus for Charlie’s – and for our potential strategic partners – has improved. Dramatically.”

Charlie’s will monetize the Company’s PMTAs through new strategic partnerships

In 2025, in three separate transactions, Charlie’s sold sixteen of the Company’s PACHA synthetic nicotine PMTA products and related assets for $7.5 million in cash plus a contingent one-time payment of up to $4.2 million. In the last of the three transactions, the buyer purchased a single Charlie’s PMTA product for $1 million. Based on these sales, taking into account the fact that Charlie’s continues to own 678 PMTA products, and considering the interest other companies have expressed in Charlie’s portfolio, the Company believes Charlie’s remaining PMTA products, as a stand-alone asset, could have a monetary value that significantly exceeds the Company’s current market cap.

Financial Results for the Three Months Ended September 30, 2026:

  • Revenue: For the three months ended September 30, 2026 revenue was $2.7 million, a decrease of $3.4 million, or 56%, compared with $6.1 million for the three months ended September 30, 2025. This decrease was primarily due to a significant decrease in sales of the SBX product line, from ongoing inconsistency in regulatory enforcement affecting customers’ desire for non-nicotine based vapor products. The decline in sales was offset by the launch of USA-made Pachamama line and sales of Pacha disposable products that are still under substantive review with FDA.
  • Gross Profit: For the three months ended September 30, 2026 gross profit was $0.1 million, a decrease of $1.5 million, or 92%, compared with $1.6 million for the three months ended September 30, 2025.
  • Total Operating Expenses: For the three months ended September 30, 2026, total operating expenses, including general and administrative, sales and marketing and research and development costs, were $1.8 million, a decrease of $0.2 million, or 10%, compared with $2.0 million for the three months ended September 30, 2025.
  • Operating Loss: For the three months ended September 30, 2026, operating loss was $1.7 million, compared with an operating loss of $0.4 million for the three months ended September 30, 2025.

Financial Results for the Nine Months Ended September 30, 2026:

  • Revenue: For the nine months ended September 30, 2026 revenue was $11.3 million, an increase of $1.8 million, or 19%, compared with $9.5 million for the nine months ended September 30, 2025. This increase was all due to the increase in nicotine-based product and nicotine alternative products sales. Sales of SBX, a non-nicotine, disposable vapor product which is not subject to FDA review, experienced a significant increase in the early part of 2026.
  • Gross Profit: For the nine months ended September 30, 2026 gross profit was $2.4 million, a decrease of $0.1 million, or 3%, compared with $2.5 million for the nine months ended September 30, 2025.
  • Total Operating Expenses: For the nine months ended September 30, 2026, total operating expenses, including general and administrative, sales and marketing and research and development costs, were $6.3 million, an increase of $1.6 million, or 34%, compared with $4.7 million for the nine months ended September 30, 2025.
  • Operating Loss: For the nine months ended September 30, 2026, operating loss was $3.9 million, compared with an operating loss of $2.2 million for the nine months ended September 30, 2025.

About Charlie’s Holdings, Inc.

Charlie’s Holdings, Inc. (OTCQB: CHUC) is an industry leader in the premium vapor products space. The Company’s products are sold around the world to select distributors, specialty retailers, and third-party online resellers through subsidiary company Charlie’s Chalk Dust, LLC. Charlie’s Chalk Dust has developed an extensive portfolio of brand styles, flavor profiles, and innovative product formats.

For additional information, please visit Charlie’s corporate website at: Chuc.com and the Company’s branded online websites: sbxvape.com, CharliesChalkDust.com, enjoypachamama.com, and Pacha.co.

Safe Harbor Statement 

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company’s overall business, existing and anticipated markets and expectations regarding future sales and expenses. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms, and similar expressions, are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ongoing ability to quote its shares on the OTCQB; whether the Company will meet the requirements to up-list to a national securities exchange in the future; the Company’s ability to successfully increase sales and enter new markets; whether the Company’s PMTAs for its nicotine-containing products will be authorized by the FDA, and the FDA’s decisions with respect to the Company’s future PMTAs for nicotine products; the Company’s ability to manufacture and produce products for its customers; the Company’s ability to formulate new products; the acceptance of existing and future products; the complexity, expense and time associated with compliance with government rules and regulations affecting nicotine, synthetic nicotine, products containing nicotine substitutes, and products containing cannabidiol; litigation risks from the use of the Company’s products; risks of government regulations; the impact of competitive products; and the Company’s ability to maintain and enhance its brands, as well as other risk factors included in the Company’s most recent quarterly report on Form 10-Q, annual report on Form 10-K, and other SEC filings. These forward-looking statements are made as of the date of this press release and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Investor Contact:
IR@charliesholdings.com
Phone: 949-570-0691

KUALA LUMPUR, Malaysia, Nov. 20, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

On May 19, 2026, the Company previously disclosed that, on May 15, 2026, the Company received a letter from Nasdaq notifying the Company that based on the closing bid price of the ordinary shares of the Company for the prior 30 consecutive business days, the Company was not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share.

On November 9, 2026, the Company’s ordinary shares began trading on a post-consolidation basis following the Company’s previously announced 1-for-5 share consolidation.

On November 16, 2026, the Company received a letter from the Nasdaq Listing Qualifications Staff stating that the Company had not regained compliance with Nasdaq Listing Rule 5450(a)(1), which required the listed ordinary shares to maintain a closing bid price of $1.00 per share for 10 consecutive business days, by November 11, 2026, the end of the applicable compliance period, and that the Staff had determined that the Company’s ordinary shares would be subject to delisting.

On November 20, 2026, the Nasdaq Listing Qualifications Staff notified the Company that the closing bid price of its ordinary shares had been $1.00 per share or greater for 10 consecutive business days, from November 9, 2026 to November 20, 2026. Accordingly, the Company has regained compliance with the minimum bid price requirement, and Nasdaq has confirmed that the matter is now closed.

The notification has no effect on the trading of the Company’s ordinary shares which continue to trade on The Nasdaq Global Market under the symbol “ALPS.”

About Alps Group Inc

Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.

Forward-Looking Statements

Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

Investor Relations Contact
Alps Group Inc
Investor Relations
Phone: +60 3-2163 1113
Email: investorrelations@alpsmedical.com

Third-quarter revenue of $11.2 million increased from $8.2 million in the second quarter; year-over-year results continued to reflect lower residential demand following the expiration of the Section 25D federal residential tax credit.

Commercial revenue increased 20% year-over-year to $2.7 million; SG&A expense declined 37% year-over-year to $4.3 million.

Results included $9.8 million of non-cash goodwill and intangible asset impairment charges.

SUNation continues to prioritize liquidity, cost management, and execution of its proposed merger with Suniva.

RONKONKOMA, N.Y., Nov. 20, 2026 (GLOBE NEWSWIRE) — SUNation Energy, Inc. (Nasdaq: SUNE) (“SUNation” or the “Company”), a leading provider of residential and commercial solar energy systems, battery storage solutions and comprehensive energy services, today announced financial results for the third quarter ended September 30, 2026 (“Q3 2026”).

Third-quarter revenue increased sequentially to $11.2 million from $8.2 million, and gross margin improved to 30.8% from 26.1%, reflecting higher revenue across the Company’s New York and Hawaii operations. Year-over-year performance continued to reflect downward pressure from the residential solar market’s adjustment to the expiration of the Section 25D federal residential tax credit at the end of 2025 under the One Big Beautiful Bill Act (“OBBBA”). Consolidated revenue declined 41% year over year, with lower residential revenue partially offset by growth in commercial revenue.

SUNation Reduces Costs and Advances Suniva Merger

The Company continued to manage its cost structure, reducing selling, general and administrative (“SG&A”) expense by 37% year over year. Results also included $9.8 million of non-cash goodwill and intangible asset impairment charges following an assessment of asset recoverability in light of lower forecast revenue and operating results. Including these charges, SUNation reported an operating loss of $11.7 million and a net loss of $11.8 million.

SUNation also continued to advance its proposed reverse merger with Suniva, Inc. (“Suniva”). SUNation currently anticipates closing in the first quarter of 2027, subject to satisfaction or waiver of applicable closing conditions and receipt of required approvals and regulatory clearances.

Q3 2026 HIGHLIGHTS

  • Revenue and gross margin improved sequentially
    Revenue increased to $11.2 million from $8.2 million in Q2 2026, and gross margin improved to 30.8% from 26.1%. Revenue declined 41% year over year, primarily reflecting lower residential installation activity.
  • Commercial revenue grew 20% year over year
    Commercial revenue reached $2.66 million, compared with $2.23 million in Q3 2025, primarily driven by growth in New York.
  • SG&A expense declined 37% year over year
    SG&A expense decreased to $4.33 million from $6.90 million, reflecting lower selling and marketing expenses and personnel cost reductions.
  • Net loss reflected non-cash impairment charges
    Net loss was $11.82 million, compared with $0.39 million in Q3 2025. Results included $9.82 million of non-cash goodwill and intangible asset impairment charges reflecting lower forecast revenue and operating results.
  • Suniva merger process advanced
    The companies amended their merger agreement during the quarter to address financing, stockholder approvals and closing requirements. Closing is currently anticipated in Q1 2027, subject to applicable conditions and approvals.

Commercial Growth Supports Revenue Diversification

The quarter’s sequential revenue and gross-margin improvement occurred within a residential market that continued to operate below prior-year activity levels. Residential revenue declined 52% year over year, while commercial revenue increased 20%. Commercial and service revenue together represented approximately 33% of consolidated revenue, compared with approximately 18% in Q3 2025.

The prior-year quarter also benefited from residential demand ahead of the year-end 2025 tax credit expiration, contributing to the year-over-year comparison. Management continues to emphasize commercial projects, battery storage, service and adjacent energy offerings as part of its efforts to diversify revenue.

Storage Opportunities Support Adaptation to Residential Market Changes

The expiration of the Section 25D federal residential tax credit at year-end 2025 under OBBBA continued to affect residential demand, installation volumes and financing economics during Q3 2026, following elevated activity ahead of the expiration. Lower installation volumes also increased fixed labor and overhead costs as a percentage of revenue.

Battery storage remains an area of focus. Hawaii’s Bring Your Own Device Plus program provides incentives for qualifying customers to add storage to existing or new rooftop solar systems. Hawaii Energy Connection’s battery attachment rates increased 13% year over year during the quarter.

Updated Asset Values and Liquidity Priorities

The Company’s impairment assessment reflected a material reduction in forecast revenue and operating results. Goodwill impairment charges related to the SUNation Residential and SUNation Commercial reporting units, while intangible asset impairment charges related to tradenames and trademarks across the New York and Hawaii businesses.

SUNation continues to prioritize cash preservation, disciplined working capital management and additional financing to support operations and maintain financial flexibility. The Company ended the quarter with $2.79 million in cash and cash equivalents and requires additional capital to meet its obligations and operating needs.

MANAGEMENT COMMENTARY

“Third-quarter revenue and gross margin improved from the second quarter as activity increased across our New York and Hawaii businesses,” said Scott Maskin, Chief Executive Officer of SUNation. “Commercial revenue grew 20% year over year, and commercial and service work represented a larger share of our business. Residential demand continues to reflect the change in customer economics following the expiration of the federal residential tax credit, and our teams remain focused on matching our offerings and operating structure to the market we are serving.”

Mr. Maskin continued, “Our priorities remain disciplined execution, customer service, cost management and liquidity. We are pursuing commercial projects, storage installations, service work, roofing and adjacent energy opportunities while managing expenses closely. We also continued to advance the Suniva merger process during the quarter, including an amendment to the merger agreement addressing financing and closing-related matters.”

James Brennan, SUNation’s Chief Financial Officer and Chief Operations Officer, said, “Higher sequential revenue supported gross-margin improvement to 30.8%, while year-over-year SG&A expense declined 37% following reductions in selling, marketing and personnel costs. Our reported results also included $9.8 million of non-cash impairment charges reflecting the effect of lower forecast revenue and operating results on the carrying value of goodwill and intangible assets.”

Mr. Brennan added, “Cash preservation, working capital management and access to additional capital remain essential. We ended September with $2.8 million of cash and cash equivalents, and our working capital position continues to require close management. We are evaluating financing sources and managing our obligations while supporting customer commitments and the proposed transaction.”

Mr. Maskin concluded, “We currently anticipate completing the Suniva merger in the first quarter of 2027, subject to the required conditions and approvals. Our immediate responsibility is to operate the business carefully through that process, serve our customers and preserve financial flexibility. The experience of our teams in New York and Hawaii, our customer relationships and our range of energy services remain important foundations as we navigate the current market.”

Q3 2026 FINANCIAL AND OPERATIONAL RESULTS

FINANCIAL RESULTS

  • Revenue
    Consolidated revenue was $11.20 million, compared with $18.99 million in Q3 2025, a decrease of 41%. Residential contract revenue declined 52%, partially offset by 20% growth in commercial revenue.
  • Gross profit and margin
    Gross profit was $3.45 million, compared with $7.21 million in Q3 2025. Gross margin was 30.8%, compared with 38.0% in the prior-year quarter, reflecting lower revenue and fixed labor and overhead costs that declined more slowly than sales volume. Gross profit and margin improved sequentially from approximately $2.1 million and 26.1%, respectively, in Q2 2026.
  • Operating expenses and cost reductions
    Total operating expenses were $15.16 million, compared with $7.46 million in Q3 2025, including $9.82 million of non-cash goodwill and intangible asset impairment charges and $0.46 million of Suniva merger transaction costs. SG&A expense declined 37% to $4.33 million from $6.90 million, reflecting lower selling and marketing expenses and personnel cost reductions.
  • Net loss
    Net loss was $11.82 million, or $1.81 per basic and diluted share, compared with $0.39 million, or $0.12 per basic and diluted share, in Q3 2025. The increase reflected the impairment charges and lower gross profit, partially offset by reduced SG&A expense. Operating loss was $11.71 million, compared with $0.25 million in Q3 2025. Impairment charges comprised $4.92 million of goodwill and $4.90 million of intangible assets. Amortization expense was unchanged year over year at $0.56 million.

For the nine months ended September 30, 2026, revenue was $26.56 million, gross profit was $7.17 million and SG&A expense was $13.87 million, compared with $44.69 million, $16.48 million and $19.38 million, respectively, in the prior-year period. Net loss, including the third-quarter impairment charges, was $19.25 million, compared with $13.50 million in the prior year.

BALANCE SHEET AND LIQUIDITY

The following comparisons are with December 31, 2025, unless otherwise indicated.

  • Cash and working capital
    Cash and cash equivalents were $2.79 million at September 30, 2026, compared with $7.18 million at year-end. The Company had a working capital deficit of $5.35 million, compared with positive working capital of $1.07 million. Net cash used in operating activities during the first nine months of 2026 was $6.54 million, partially offset by $2.11 million of net cash provided by financing activities.
  • Payables and loans payable
    Accounts payable declined 23% to $5.66 million from $7.40 million. The aggregate carrying amount of current and long-term loans payable and related interest, including related-party balances, declined to $4.98 million from $6.60 million, reflecting repayments, the related-party debt conversion completed earlier in 2026 and borrowings under the affiliated revolving credit facility.
  • Credit facility extension
    On October 15, 2026, the maturity of the Company’s $1.5 million affiliated revolving credit facility was extended to April 15, 2027. Borrowings outstanding were $0.80 million at September 30, 2026, and the Company was in compliance with the facility’s covenants and other requirements at that date.

Total liabilities were $22.78 million, compared with $23.90 million at year-end. Current liabilities increased to $16.96 million from $15.41 million, while long-term liabilities declined to $5.82 million from $8.49 million. Stockholders’ equity was $8.69 million, compared with $24.35 million at year-end and $20.52 million at June 30, 2026, with the sequential decline primarily reflecting the third-quarter net loss, including impairment charges.

The Company requires additional capital resources and is considering all available options, including the ongoing strategic initiatives previously announced. The availability, timing, and terms of any additional funding remains undetermined.

OPERATIONAL RESULTS

  • Residential revenue
    Consolidated residential contract revenue was $7.53 million, compared with $15.66 million in Q3 2025, reflecting lower installation activity in New York and.
  • Commercial revenue
    Consolidated commercial contract revenue increased 20% to $2.66 million from $2.23 million, primarily driven by New York, where commercial revenue increased to $2.63 million from $2.23 million.
  • Service revenue
    Consolidated service revenue was $1.01 million, compared with $1.11 million in Q3 2025. Hawaii service revenue increased 54% to $0.37 million, supported by increased repair and replacement installations, partially offsetting lower New York service revenue.

By operating segment, SUNation NY reported revenue of $8.01 million and gross profit of $2.61 million, compared with $13.01 million and $5.29 million, respectively, in Q3 2025. HEC reported revenue of $3.19 million and gross profit of $0.84 million, compared with $5.98 million and $1.92 million, respectively. Hawaii’s lower residential installation volumes were partially offset by higher price per watt, increased battery attachment rates and service growth.

The Company continues to evaluate product offerings and financing options to support solar and storage adoption while pursuing commercial, service, roofing and adjacent energy opportunities.

STRATEGIC INITIATIVES AND PROPOSED SUNIVA MERGER

SUNation continued to advance its proposed reverse merger with Suniva during Q3 2026. The transaction, announced in June following the Board’s review of strategic alternatives, would result in Suniva becoming a wholly owned subsidiary of SUNation.

On September 4, 2026, the parties amended the merger agreement to address financing arrangements, stockholder approvals and closing requirements. The amendment revised SUNation’s closing net cash requirement to negative $2.5 million, subject to adjustment for potential capital raises, and added a proposed increase in authorized common shares from 1.0 billion to 1.5 billion to the matters requiring stockholder approval.

The amendment also provides for SUNation to use reasonable best efforts to repay or convert into equity up to approximately $2.61 million of specified related-party loans. Any conversion would be at $2.26 per share and subject to stockholder approval (with any related parties abstaining from the vote). These arrangements remain subject to the merger agreement, as amended.

The Company has confidentially submitted a registration statement on Form S-4 containing a proxy statement/prospectus relating to the proposed transaction. Closing remains subject to required stockholder approvals, effectiveness of the registration statement, Nasdaq listing approval and other applicable closing conditions and regulatory clearances. The timing and completion of the transaction remain uncertain.

Alongside the merger process, SUNation continued to manage its capital resources. During the first nine months of 2026, the Company completed a private placement generating approximately $2.7 million in gross proceeds for working capital and general corporate purposes, converted $1.2 million of related-party note principal into equity and made approximately $1.2 million of payments against third-party and related-party loans.

BUSINESS STRATEGY AND OUTLOOK

SUNation’s near-term priorities are to preserve liquidity, manage working capital, align costs with current revenue levels and advance the proposed Suniva merger. Management expects residential demand and installation activity to remain sensitive to customer financing economics and the market’s adjustment to the expiration of the Section 25D federal residential tax credit.

The Company remains focused on serving customers in New York and Hawaii while diversifying revenue through commercial projects, battery storage, maintenance and repair, roofing and adjacent energy services. Management will continue to evaluate financing alternatives to support operations and maintain financial flexibility as it pursues these priorities.

ABOUT SUNATION ENERGY, INC.

SUNation Energy Inc. (Nasdaq: SUNE) is a leading provider of sustainable solar energy and backup power solutions to residential, commercial, and municipal customers. The Company designs, installs, and services solar energy systems and related technologies, helping customers reduce energy costs, increase energy independence, and transition to cleaner energy solutions.

For more information, visit: ir.sunation.com

ABOUT SUNIVA

Headquartered in metro Atlanta, Georgia, Suniva is the leading American manufacturer of high-efficiency crystalline silicon photovoltaic (PV) solar cells. As the only U.S.-owned and operated solar cell manufacturer in the country, the company is known for its high-quality products, industry-leading technology, reliability, and high-power density. For more information, visit www.suniva.com.

CONTACTS

Scott Maskin, Chief Executive Officer
SUNation Energy, Inc.
smaskin@sunation.com

James Brennan, Chief Financial Officer
SUNation Energy, Inc.
jbrennan@sunation.com

Investor Relations
Alliance Advisors IR
IR@sunation.com

FORWARD-LOOKING STATEMENTS

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that are not historical facts and may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “estimate,” “plan,” “project,” “target,” “design,” “will,” “would”, “could”, “should”, “may”, “forecast”, “potential”, “target” and similar expressions.

These statements include, but are not limited to, statements regarding: the projected funding status, capacity, and completion and production ramp schedule of Suniva’s Laurens County project; the benefits of the project to Laurens County, including job creation projections, the State of South Carolina and the nation’s energy infrastructure and independence; the efficacy of Suniva’s supply chain and long-term product offtake agreements to achieve their intended purposes; and any statements regarding the proposed merger of SUNation and Suniva.

These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others: risks relating to constructing, equipping, permitting and ramping up the Laurens facility on time and on budget; the ability to convert offtake agreements into realized revenue; competition, tariffs, trade actions and changes in tax incentives, including the Section 45X advanced manufacturing production credit; technology, supply-chain and execution risks; the accuracy of third-party market data and forecasts; the operating history of Suniva; potential net losses incurred as a result of the current expansion stage nature of Suniva, as well as net losses carried forward from SUNation’s long standing business operations after the completion of the merger; the ability to raise additional capital; the ability of Suniva to execute on its business plans and for the combined companies to integrate SUNation’s solar installation systems into Suniva’s solar cell manufacturing operations; the effects of the One Big Beautiful Act of 2025 on the residential solar industry, which has had a material negative impact on residential solar installations since the January 2026 effectiveness thereof; Suniva’s limited experience in operating a public company; the substantial competition Suniva faces in developing and selling its solar cell development products; the ability to attract, hire, and retain skilled executive officers and employees; the ability of SUNation or Suniva to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; the risk that the risk that the proposed merger may not be completed on the anticipated timeline or at all; the failure to obtain required stockholder approvals, SEC effectiveness of the Form S-4 registration statement, or Nasdaq listing approval; the parties’ ability to satisfy the conditions to closing and to close expected financing; uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of the parties to consummate the proposed transactions; risks related to SUNation’s continued listing on Nasdaq until the closing of the proposed transactions; risks related to SUNation’s and Suniva’s ability to correctly estimate their respective operating expenses and expenses associated with the proposed transactions, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement; competitive responses to the proposed transactions; unexpected costs, charges or expenses resulting from the proposed transactions; the outcome of any legal proceedings that may be instituted against SUNation, Suniva or any of their respective directors or officers related to the Merger or the proposed transactions contemplated thereby; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transactions; the effect of the announcement or pendency of the transactions on SUNation’s or Suniva’s business relationships, operating results and business generally; the compliance and qualification for initial listing on Nasdaq related to the expected trading of the combined company’s stock on Nasdaq and the combined company’s ability to remain listed following the proposed transactions; the risk that as a result of adjustments to the Exchange Ratio (as set forth in the Merger Agreement) SUNation’s stockholders and Suniva’s stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of SUNation common stock relative to the Exchange Ratio; legislative, regulatory, political and economic developments and general market conditions, including those surrounding the viability of residential solar businesses following the loss of federal tax credits beginning in January 2026; and the other risks described in SUNation’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and to be described in the Form S-4 and related proxy statement/prospectus.

These forward-looking statements speak only as of the date of this press release. Suniva and SUNation expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in expectations or any change in events, conditions or circum-stances on which any such statement is based, except as required by law.

NO OFFER OR SOLICITATION

This communication is for informational purposes only and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transactions or (ii) an offer to sell or buy, or the solicitation of an offer to sell or buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, email, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESS RELEASE IS TRUTHFUL OR COMPLETE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

This press release is not a substitute for the registration statement or for any other document that SUNation may file with the U.S. Securities and Exchange Commission (“SEC”) in connection with the proposed transactions. In connection with the proposed Merger transaction, SUNation intends to file with the SEC a registration statement on Form S-4 that will include a proxy statement of SUNation and a prospectus (the “proxy statement/prospectus”). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents, when available, at the SEC’s website at www.sec.gov. In addition, investors and stockholders should note that SUNation communicates with investors and the public using its website (www.sunation.com) and the investor relations website, (https://ir.sunation.com/), where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by SUNation with the SEC and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transactions.

PARTICIPANTS IN THE SOLICITATION

SUNation, Suniva and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from SUNation’s shareholders in respect of the proposed transaction. Information regarding SUNation’s directors and executive officers is set forth in SUNation’s most recent Annual Report on Form 10-K, including any information incorporated by reference, as filed with the SEC on March 23, 2026, as supplemented by its periodic SEC reports thereafter. Additional information regarding the participants in the solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available.

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

Table 3: Consolidated Operating Results

                             
  Three Months Ended September 30          
  2026   2025   Change
(In Thousands, except per share data)   Amount   % of Sales     Amount   % of Sales     $   %
                             
Sales $ 11,201     100 %   $ 18,994     100 %   $ (7,793 )   -41.0 %
Cost of sales   7,747     69 %     11,782     62 %     (4,035 )   -34.3 %
Gross profit   3,454     31 %     7,212     38 %     (3,758 )   -52.1 %
Operating expenses:                            
Selling, general and administrative expenses   4,327     39 %     6,898     36 %     (2,571 )   -37.3 %
Amortization expense   559     5 %     559     3 %     —     0.0 %
Transaction costs   457     4 %     —     0 %     457     NM
Goodwill impairment loss   4,918     44 %     —     0 %     4,918     NM
Intangible asset impairment loss   4,901     44 %     —     0 %     4,901     NM
Total operating expenses   15,162     135 %     7,457     39 %     7,705     103.3 %
Operating loss   (11,708 )   -105 %     (246 )   -1 %     (11,462 )   4664.6 %
Other income (expense):                            
Investment and other income   12     0 %     15     0 %     (3 )   -22.1 %
Gain on sale of assets   32     0 %     —     0 %     32     NM
Fair value remeasurement of contingent value rights   —     0 %     (2 )   0 %     2     -100.0 %
Interest expense   (162 )   -1 %     (144 )   -1 %     (18 )   13.3 %
Other expense, net   (118 )   -1 %     (131 )   -1 %     13     -9.5 %
Net loss before income taxes   (11,826 )   -106 %     (376 )   -2 %     (11,450 )   3042.8 %
Income tax (benefit) expense   (6 )   0 %     17     0 %     (23 )   -135.9 %
Net loss $ (11,820 )   -106 %   $ (393 )   -2 %   $ (11,427 )   2907.9 %
                             
Basic and diluted net loss per share $ (1.81 )       $ (0.12 )              
Weighted average basic and dilutive shares   6,513,108           3,406,614                
                                 


CONSOLIDATED BALANCE SHEET HIGHLIGHTS

(In thousands)

Table 4: Balance Sheet Highlights

  September 30 June 30 September 30
  2026 2026 2025
Cash and cash equivalents $ 2,787   $ 3,061   $ 5,415  
Current assets   11,610     10,549     17,170  
Total assets   31,463     40,922     49,607  
Current liabilities   16,957     13,773     19,034  
Total liabilities   22,778     20,398     27,879  
Total stockholders’ equity (deficit)   8,685     20,524     21,728  
Working capital   (5,347 )   (3,224 )   (1,865 )
                   

CONSOLIDATED CASH FLOW SUMMARY

(In thousands)

Table 5: Cash Flow Summary

  Three Months Ended
  September 30 June 30 September 30
  2026 2026 2025
Net cash (used in) provided by operating activities $ (276 ) $ (1,100 ) $ 2,387  
Net cash provided by (used in) investing activities   33     (2 )   (9 )
Net cash (used in) provided by financing activities   (31 )   2,477     (148 )
Net (decrease) increase in cash, cash equivalents,
and restricted cash
  (274 )   1,375     2,230  
Cash, cash equivalents and restricted cash at
beginning of period
  3,061     1,687     3,474  
Cash, cash equivalents and restricted cash at end of
period
  2,787     3,061     5,704  

  Nine Months Ended September 30
  2026   2025
Net cash used in operating activities $ (6,540 )   $ (1,146 )
Net cash provided by (used in) investing activities   34       (18 )
Net cash provided by financing activities   2,111       5,716  
Net (decrease) increase in cash, cash equivalents, and restricted cash   (4,395 )     4,552  
Cash, cash equivalents and restricted cash at beginning of period   7,182       1,152  
Cash, cash equivalents and restricted cash at end of period $ 2,787     $ 5,703  
               


SEGMENT PERFORMANCE SUMMARY

(In thousands)

Table 6: SUNation NY Segment Results

  Three Months Ended September 30
  2026   2025
Revenue $ 8,007     $ 13,015  
Gross profit   2,612       5,291  
Gross margin   32.6 %     40.7 %
Operating (loss) income   (6,946 )     4,415  
               

Table 7: Hawaii Energy Connection Segment Results

  Three Months Ended September 30
  2026   2025
Revenue $ 3,193     $ 5,979  
Gross profit   842       1,920  
Gross margin   26.4 %     32.1 %
Operating loss   (3,647 )     444  
               


ADJUSTED EBITDA RECONCILIATION

Non-GAAP Financial Measures

This press release also includes non-GAAP financial measures that differ from financial measures calculated in accordance with United States generally accepted accounting principles (“GAAP”). Adjusted EBITDA is a non-GAAP financial measure provided in this release, and is net loss calculated in accordance with GAAP, adjusted for interest, income taxes, depreciation, amortization, stock compensation, transaction costs, gain on sale of assets, earnout consideration compensation, financing fees, and non-cash fair value remeasurement adjustments as detailed in the reconciliations presented below in this press release.

These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these measures principally as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors, and other interested parties to evaluate companies in its industry. The Company also believes these non-GAAP financial measures are useful to its management and investors as a measure of comparative operating performance from period to period.

The non-GAAP financial measures presented in this release should not be considered as an alternative to, or superior to, their respective GAAP financial measures, as measures of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, these measures do not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

Table 8: Reconciliation of GAAP Net Loss To Adjusted EBITDA

  Three Months Ended September 30
    2026       2025  
Net Loss $ (11,820,205 )   $ (392,975 )
Interest expense   162,445       143,420  
Interest income   (5,279 )     (9,670 )
Income taxes   (5,981 )     16,679  
Depreciation   62,688       68,674  
Amortization   559,375       559,375  
Transaction costs   456,889       —  
Goodwill impairment loss   4,917,533       —  
Intangible asset impairment loss   4,900,884       —  
Stock compensation   (18,158 )     18,899  
Earnout consideration compensation   —       491,130  
Gain on sale of assets   (32,532 )     —  
FV remeasurement of contingent value rights   —       2,318  
Adjusted EBITDA $ (822,341 )   $ 897,850  
               

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.